Achieve Life Sciences ACHV Convertible Debt (Non-Current)
Convertible Debt (Non-Current) at other companies
Other financials
Where this comes from
Reported directly by Achieve Life Sciences in its filing.
Tagged under the XBRL concept us-gaap:ConvertibleDebtNoncurrent.
The official record: Achieve Life Sciences’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Achieve Life Sciences's convertible debt (non-current).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Achieve Life Sciences's convertible debt (non-current)?
- Achieve Life Sciences (ACHV) reported convertible debt (non-current) of $9.32M in Q1 2026.
- How has Achieve Life Sciences's convertible debt (non-current) changed year-over-year?
- Achieve Life Sciences's convertible debt (non-current) increased by 7.7% year-over-year, from $8.66M to $9.32M.
- What is the long-term trend for Achieve Life Sciences's convertible debt (non-current)?
- Over 2 years (2021 to 2025), Achieve Life Sciences's convertible debt (non-current) has grown at a -13.4% compound annual growth rate (CAGR), from $14.92M to $11.19M.
- What does convertible debt (non-current) mean?
- This represents the principal amount of long-term debt obligations that carry the option to be converted into equity shares of the company. It is a critical component of the capital structure that balances debt financing with potential future dilution for existing shareholders. Investors analyze this to evaluate the company's long-term leverage and the potential impact of conversion on earnings per share.